Sandoz: #SandozHACk #tweetchat
•Download as PPTX, PDF•
0 likes•284 views
On November 9, 2016, Sandoz held a #tweetchat focused on ways to increase access to medicines and the major challenges facing healthcare systems over the next 5-10 years.
Report
Share
Report
Share
Recommended
Pioneering novel approaches to increase access for patients worldwide
Sandoz aims to pioneer novel approaches to increase access to high-quality healthcare for patients worldwide. In 2015, Sandoz reached 520 million patient lives and their aspiration is to reach one billion. Biosimilars are key to their goal of increasing access, as they can play a transformational role by generating savings for healthcare systems, increasing supply of medicines, and improving patient access to life-saving treatments.
Eyeforpharma 2017
Richard Francis, Division Head and CEO, Sandoz presentation to Eyeforpharam conference 2017 on healthcare system sustainability and the role of generics and biosimilars
Sunday 2 per spindler introduction biopeople
The document discusses Denmark's efforts to promote collaboration and partnerships between biotech companies through Biopeople, Denmark's Innovation Network for Health & Life Sciences. Biopeople helps small and medium biotech companies establish national and international collaborations through activities like partnering missions and networking events. Several Danish political leaders have stated that biotechnology is a success story and growth area for Denmark where the country is a global leader, and Biopeople plays a key role in providing small biotech companies access to international partnerships. The document also briefly mentions Denmark's national innovation and cluster strategies that aim to promote international partnerships between clusters.
Novartis
Novartis is a global healthcare company headquartered in Switzerland that employs over 115,000 people worldwide. It was created in 1996 through the merger of Ciba-Geigy and Sandoz. Novartis operates in India through four entities and has a presence in pharmaceuticals, generics, vaccines, consumer health, eye care, and animal health. Some of Novartis' most visible and successful products include the diabetes drug Galvus, the hypertension drug Diovan, and the anticonvulsant Tegretol.
Novartis india
Novartis has been operating in India since 1947 through various entities. It has a presence in pharmaceuticals, generics, vaccines, over-the-counter medicines, and eye care. Novartis' mission is to discover, develop, and market innovative products to prevent and cure diseases while enhancing quality of life. Its vision is to provide shareholder returns through outstanding performance. Novartis invests heavily in research and development through its institute and sees R&D as key to innovation and meeting unmet medical needs.
Expanding Sandoz leadership in biosimilars
A short presentation on the challenges and opportunities of biosimilars and the role they can play in access to medicine
The Biosimilar Market Leader’s Perspective
At least 400 million people worldwide lack access to essential health services and 2 billion cannot afford the medicines they need. Meanwhile, the global cost of healthcare has jumped to 6.5 trillion US dollars. Access is a huge and complex issue, which affects both developing and developed countries.
Today Carol Lynch, our Global Head of Biopharmaceuticals, gave a keynote address to the European Biosimilars Group highlighting how biosimilars can help transform patient outcomes and calling for all stakeholders to work together to build trust and confidence. You can read the presentation here
14. Dr. Thomas Kirchlechner - Sandoz Biopharmaceuticals Development
14. Dr. Thomas Kirchlechner - Sandoz Biopharmaceuticals DevelopmentInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
“Challenges of biosimilar product development and experience gained”
Shows the development process for biosimilars, focusing specifically on the company’s experienceRecommended
Pioneering novel approaches to increase access for patients worldwide
Sandoz aims to pioneer novel approaches to increase access to high-quality healthcare for patients worldwide. In 2015, Sandoz reached 520 million patient lives and their aspiration is to reach one billion. Biosimilars are key to their goal of increasing access, as they can play a transformational role by generating savings for healthcare systems, increasing supply of medicines, and improving patient access to life-saving treatments.
Eyeforpharma 2017
Richard Francis, Division Head and CEO, Sandoz presentation to Eyeforpharam conference 2017 on healthcare system sustainability and the role of generics and biosimilars
Sunday 2 per spindler introduction biopeople
The document discusses Denmark's efforts to promote collaboration and partnerships between biotech companies through Biopeople, Denmark's Innovation Network for Health & Life Sciences. Biopeople helps small and medium biotech companies establish national and international collaborations through activities like partnering missions and networking events. Several Danish political leaders have stated that biotechnology is a success story and growth area for Denmark where the country is a global leader, and Biopeople plays a key role in providing small biotech companies access to international partnerships. The document also briefly mentions Denmark's national innovation and cluster strategies that aim to promote international partnerships between clusters.
Novartis
Novartis is a global healthcare company headquartered in Switzerland that employs over 115,000 people worldwide. It was created in 1996 through the merger of Ciba-Geigy and Sandoz. Novartis operates in India through four entities and has a presence in pharmaceuticals, generics, vaccines, consumer health, eye care, and animal health. Some of Novartis' most visible and successful products include the diabetes drug Galvus, the hypertension drug Diovan, and the anticonvulsant Tegretol.
Novartis india
Novartis has been operating in India since 1947 through various entities. It has a presence in pharmaceuticals, generics, vaccines, over-the-counter medicines, and eye care. Novartis' mission is to discover, develop, and market innovative products to prevent and cure diseases while enhancing quality of life. Its vision is to provide shareholder returns through outstanding performance. Novartis invests heavily in research and development through its institute and sees R&D as key to innovation and meeting unmet medical needs.
Expanding Sandoz leadership in biosimilars
A short presentation on the challenges and opportunities of biosimilars and the role they can play in access to medicine
The Biosimilar Market Leader’s Perspective
At least 400 million people worldwide lack access to essential health services and 2 billion cannot afford the medicines they need. Meanwhile, the global cost of healthcare has jumped to 6.5 trillion US dollars. Access is a huge and complex issue, which affects both developing and developed countries.
Today Carol Lynch, our Global Head of Biopharmaceuticals, gave a keynote address to the European Biosimilars Group highlighting how biosimilars can help transform patient outcomes and calling for all stakeholders to work together to build trust and confidence. You can read the presentation here
14. Dr. Thomas Kirchlechner - Sandoz Biopharmaceuticals Development
14. Dr. Thomas Kirchlechner - Sandoz Biopharmaceuticals DevelopmentInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
“Challenges of biosimilar product development and experience gained”
Shows the development process for biosimilars, focusing specifically on the company’s experienceSandoz Company Presentation
Sandoz reached 520 million patients worldwide in 2015 and aims to reach one billion patients by expanding access to medicine. The presentation discusses the global challenge of access to healthcare, with over 2 billion people unable to access needed medicines. Sandoz is uniquely positioned within Novartis to help solve the access challenge through its broad portfolio, focus on priority markets, and leadership in generics, biosimilars, and anti-infectives.
Sandoz in Africa - a global leader
Sandoz is a global leader in generic pharmaceuticals and is part of the Novartis Group. In 2011, Sandoz had sales of $9.5 billion and reached over 400 million patients worldwide. Sandoz operates in 140 countries with around 25,000 employees and has a portfolio of over 1,100 compounds and 23,500 stock-keeping units. The document discusses Sandoz's leadership in various therapeutic areas and technologies. It also highlights Sandoz's commitment to growth in Africa through partnerships and projects aimed at improving patient care.
6 Hans Wormann - Therapiepotentiale für den Patienten optimal ausschöpfen - g...
Hans Wormanns Vortrag bei der welldoo Panorama 2014
Alyante Introduction Presentation
Alyante is a custom research services organisation that delivers quality research to help improve your research efficiencies. It provides comprehensive end-to-end solutions ranging from chemical and pharmaceutical development to product supply, including complete regulatory support for filing. To enhance your product portfolio, Alyante offers innovative services including NDDS.
Alyante’s array of innovation-based services and commitment to excellence will help you create new value.
Alyante is an assurance of an alliance that strives to keep your research always ahead of the competition through innovation and trust.
Originators and Princeps: How to face Biosimilars and Generics
Concerning the levers a originators producer can put in place to face the biosimilars competition and maintain his position, benchmarking on biosimilars, generics (13 companies from 2000 to 2015) and the results of our interview allow us to observe 10 levers:
Price Prescription
Patent Market saturation
Legal action New market
Cooperation Environmental strategy
Product Brand strategy
Tefen's Supply Chain Breakfast Meeting - Sun Pharma
Benny Klener, Senior VP, Head of Global Operations at Sun Pharma gave a lecture in Tefen's supply chain breakfast meeting, telling about Tefen's supply chain project in Sun Pharma
Diseno autorretratosccpb.
Este documento presenta cuatro autorretratos de estudiantes de diferentes orígenes culturales con el objetivo de fomentar el diálogo intercultural y la comprensión mutua. Cada autorretrato explora un tema como el concepto de cultura, los choques culturales, el papel de la escuela en la mediación cultural y la experiencia de la mujer inmigrante. El profesor utiliza estos autorretratos como punto de partida para actividades que permiten a la clase aprender sobre diferentes perspectivas culturales y ampliar su comprensión del mundo.
Analisis trimestral mercado hospitalario IMS Mar 14
El mercado hospitalario español alcanzó 6,280 M€ en 2013, un incremento del 3,6%. Las principales áreas terapéuticas (oncología, VIH, hepatitis C, AIB) representaron el 50% del mercado y crecieron entre el 1,5% y 72,8%. Se prevé estabilización del crecimiento hasta 2017 debido a genéricos y biosimilares.
Wockhardt ltd
We initiate coverage on Wockhardt Limited (Wockhardt) as a BUY with a
Price Objective of ` 978 (target 10.0x FY14 P/E). At CMP of ` 565 the stock
is trading at 3.4x and 5.8x its estimated earnings for FY2013E & FY2014E
representing a potential upside of ~73% over a period of 18 months. With
the contingent liability concerns addressed and bulk of FCCBs already
repaid, the sale of nutrition business will lead to a substantial increase in
cash which could be used to draw down debt or pursue organic / inorganic
grow opportunities. Further its portfolio of high margin niche products and
impressive FTF launches should provide for strong growth in revenues
(12.3% FY11-14 CAGR) to ` 5311.2 crore and earnings (123.6% FY11-14
CAGR) of ` 97.8 /share by FY14.
During the period 2003 through 2008, Wockhardt has traded mostly in line
with the 1 Year forward PE multiple of its peers viz: Sun Pharma, Cipla,
Lupin and Glenmark. However, post its derivative losses, Wockhardt’s EPS
turned negative. Now that the balance sheet is all cleaned up and all
contingent liabilities addressed, we expect that going forward, Wockhardt
will catch up with its peers leading to a substantial re-rating of the stock.
Case studies in Strategy: Teva
Case study in Strategy- Teva
analyzing the company and suggesting strategy for future growth and new markets
Presentation1.pptxdilip shanghvi
Dilip Shanghvi is the founder and managing director of Sun Pharmaceuticals, which he started in 1982 with Rs. 10,000 capital. Under his leadership, Sun Pharmaceuticals has grown to become India's largest drugmaker and most valuable pharmaceutical company. Shanghvi launched his career helping his father's wholesale drugs business and realized he could manufacture his own drugs. Through strategic acquisitions over the decades, Sun Pharmaceuticals now has a global presence and Shanghvi has a net worth of over $18 billion, making him one of Asia's richest self-made billionaires.
The value of generics and biosimilar drugs
Dr Paul Cornes has received salary from the UK National Health Service and honoraria from several pharmaceutical companies including Roche, Janssen, Sandoz, Lilly, European Generics Association, Teva, and Hospira. The document discusses the increasing cost of cancer drugs and argues that greater use of generics and biosimilars can help contain costs while maintaining treatment effectiveness. It provides examples showing that in the US, increased generic drug use has saved over $1 trillion in healthcare costs in the past decade through lower prices.
Dilip Shanghvi
Dilip Shanghvi founded Sun Pharmaceuticals in 1983 with a loan of Rs. 10,000 from his father. He started the company in Kolkata and later moved headquarters to Mumbai. Sun Pharma has grown to become the fifth largest drug maker in India through strategic acquisitions both in India and abroad. Shanghvi successfully turned around loss-making companies after acquiring them. Sun Pharma focuses on specialty and niche drugs, and over 70% of its sales come from India, though it also has operations in the US.
Biocon H1 q2fy10 11
This partnership between Biocon and Pfizer will enable Biocon's insulin portfolio to have a global presence. Pfizer will have exclusive commercialization rights for Biocon's biosimilar versions of insulin and insulin analogs globally. Biocon will be responsible for clinical development, manufacturing, supply, and regulatory approvals. The agreement is expected to provide upfront and milestone payments totaling $350 million to Biocon. This partnership will help expand access to affordable treatment options for diabetes patients worldwide.
HR PRACTICES AT GSK
GlaxoSmithKline (GSK) is a large British pharmaceutical company formed through a series of mergers over the past 200 years. GSK has a presence in over 170 countries and engages in research and development of pharmaceuticals, vaccines, and consumer healthcare products. The company has a strong focus on ethics and values of patient-focus, integrity, respect for people, and transparency. GSK has a long history in India dating back to 1924 and remains committed to developing and providing affordable medicines to Indian patients.
Sun pharma ranbaxy acquisition
Sun Pharma acquired Ranbaxy in 2014 in a $4 billion deal to become the largest pharmaceutical company in India and fifth largest globally. The acquisition made Sun Pharma the largest Indian pharma company in the US and provided Ranbaxy with API manufacturing capabilities to resume exports to the US. However, Sun Pharma also assumed $800 million of Ranbaxy's debt and regulatory issues remain resolving quality issues at Ranbaxy's plants that were banned by the USFDA. The merger aimed to create synergies but was expected to negatively impact Sun Pharma's financial performance in the near term.
Biosimilars
This document provides an overview of biosimilars. It discusses that biosimilars are similar versions of biologic drugs that are set to lose patent protection. This presents both opportunities to make cheaper biologics to increase access, as well as regulatory challenges to demonstrate similarity. The global biosimilars market is growing, driven by both developed and emerging markets. India is emerging as a key player, with companies developing biosimilars for both domestic and export markets. However, hurdles remain around establishing clear regulatory pathways and demonstrating similarity to reference biologics.
Biosimilars
This document discusses biosimilars and their regulation. It begins with a brief history of biotechnology and biopharmaceuticals. It then defines biosimilars as similar but not generic versions of biologic drugs whose patents have expired. The document outlines key differences between biosimilars and generic drugs, including their larger and more complex molecular structures. It also discusses concerns regarding biosimilar efficacy, safety, interchangeability, and pharmacovigilance. Finally, it provides an overview of regulatory frameworks for biosimilars in various regions like the EU, US, India, and WHO guidelines.
Creating an Integrated International Public Relations Campaign
Here is the presentation from a Public Affairs Council webinar during which I discussed my experience planning and executing a global strategy to align Pfizer with anti-athletic doping efforts.
The Finnish Health Startup Industry Report 2017
Our main goals with this report were to create an overall picture of the health and wellbeing startup industry in Finland, to promote the ecosystem and to strengthen Finland’s position in the sector. This report functions as a tool for development of activities in the ecosystem. We hope that this report gives you a better understanding of the current health startups and the challenges they face.
Don’t kill the analyst just yet – the new world of text analytics
This document is a presentation about using text analytics to accelerate insight generation. It discusses how text analytics can extract usable knowledge from unstructured text data to support decision making. Text analytics allows organizations to explore topics being discussed, sentiment, and provide a single voice of the customer experience. Two case studies are presented, one involving merging feedback from multiple sources for an airline, and another analyzing online discussions about diabetes to understand perceptions of a new drug class. Challenges of text analytics like multiple languages and garbage in/garbage out are also addressed.
Joint Working workshop
The document discusses a quality premium program that rewards clinical commissioning groups for improvements in quality and outcomes. It explains that the premium is based on performance on 4 national measures and 3 local measures selected by each CCG. The national measures relate to reducing mortality, emergency admissions, patient experience, and infections. For a sample CCG, emergency admissions are a major issue, with over 56,000 total admissions last year. Selecting local measures that help achieve the national measures, like reducing emergency admissions, could maximize the CCG's quality premium payment.
More Related Content
Viewers also liked
Sandoz Company Presentation
Sandoz reached 520 million patients worldwide in 2015 and aims to reach one billion patients by expanding access to medicine. The presentation discusses the global challenge of access to healthcare, with over 2 billion people unable to access needed medicines. Sandoz is uniquely positioned within Novartis to help solve the access challenge through its broad portfolio, focus on priority markets, and leadership in generics, biosimilars, and anti-infectives.
Sandoz in Africa - a global leader
Sandoz is a global leader in generic pharmaceuticals and is part of the Novartis Group. In 2011, Sandoz had sales of $9.5 billion and reached over 400 million patients worldwide. Sandoz operates in 140 countries with around 25,000 employees and has a portfolio of over 1,100 compounds and 23,500 stock-keeping units. The document discusses Sandoz's leadership in various therapeutic areas and technologies. It also highlights Sandoz's commitment to growth in Africa through partnerships and projects aimed at improving patient care.
6 Hans Wormann - Therapiepotentiale für den Patienten optimal ausschöpfen - g...
Hans Wormanns Vortrag bei der welldoo Panorama 2014
Alyante Introduction Presentation
Alyante is a custom research services organisation that delivers quality research to help improve your research efficiencies. It provides comprehensive end-to-end solutions ranging from chemical and pharmaceutical development to product supply, including complete regulatory support for filing. To enhance your product portfolio, Alyante offers innovative services including NDDS.
Alyante’s array of innovation-based services and commitment to excellence will help you create new value.
Alyante is an assurance of an alliance that strives to keep your research always ahead of the competition through innovation and trust.
Originators and Princeps: How to face Biosimilars and Generics
Concerning the levers a originators producer can put in place to face the biosimilars competition and maintain his position, benchmarking on biosimilars, generics (13 companies from 2000 to 2015) and the results of our interview allow us to observe 10 levers:
Price Prescription
Patent Market saturation
Legal action New market
Cooperation Environmental strategy
Product Brand strategy
Tefen's Supply Chain Breakfast Meeting - Sun Pharma
Benny Klener, Senior VP, Head of Global Operations at Sun Pharma gave a lecture in Tefen's supply chain breakfast meeting, telling about Tefen's supply chain project in Sun Pharma
Diseno autorretratosccpb.
Este documento presenta cuatro autorretratos de estudiantes de diferentes orígenes culturales con el objetivo de fomentar el diálogo intercultural y la comprensión mutua. Cada autorretrato explora un tema como el concepto de cultura, los choques culturales, el papel de la escuela en la mediación cultural y la experiencia de la mujer inmigrante. El profesor utiliza estos autorretratos como punto de partida para actividades que permiten a la clase aprender sobre diferentes perspectivas culturales y ampliar su comprensión del mundo.
Analisis trimestral mercado hospitalario IMS Mar 14
El mercado hospitalario español alcanzó 6,280 M€ en 2013, un incremento del 3,6%. Las principales áreas terapéuticas (oncología, VIH, hepatitis C, AIB) representaron el 50% del mercado y crecieron entre el 1,5% y 72,8%. Se prevé estabilización del crecimiento hasta 2017 debido a genéricos y biosimilares.
Wockhardt ltd
We initiate coverage on Wockhardt Limited (Wockhardt) as a BUY with a
Price Objective of ` 978 (target 10.0x FY14 P/E). At CMP of ` 565 the stock
is trading at 3.4x and 5.8x its estimated earnings for FY2013E & FY2014E
representing a potential upside of ~73% over a period of 18 months. With
the contingent liability concerns addressed and bulk of FCCBs already
repaid, the sale of nutrition business will lead to a substantial increase in
cash which could be used to draw down debt or pursue organic / inorganic
grow opportunities. Further its portfolio of high margin niche products and
impressive FTF launches should provide for strong growth in revenues
(12.3% FY11-14 CAGR) to ` 5311.2 crore and earnings (123.6% FY11-14
CAGR) of ` 97.8 /share by FY14.
During the period 2003 through 2008, Wockhardt has traded mostly in line
with the 1 Year forward PE multiple of its peers viz: Sun Pharma, Cipla,
Lupin and Glenmark. However, post its derivative losses, Wockhardt’s EPS
turned negative. Now that the balance sheet is all cleaned up and all
contingent liabilities addressed, we expect that going forward, Wockhardt
will catch up with its peers leading to a substantial re-rating of the stock.
Case studies in Strategy: Teva
Case study in Strategy- Teva
analyzing the company and suggesting strategy for future growth and new markets
Presentation1.pptxdilip shanghvi
Dilip Shanghvi is the founder and managing director of Sun Pharmaceuticals, which he started in 1982 with Rs. 10,000 capital. Under his leadership, Sun Pharmaceuticals has grown to become India's largest drugmaker and most valuable pharmaceutical company. Shanghvi launched his career helping his father's wholesale drugs business and realized he could manufacture his own drugs. Through strategic acquisitions over the decades, Sun Pharmaceuticals now has a global presence and Shanghvi has a net worth of over $18 billion, making him one of Asia's richest self-made billionaires.
The value of generics and biosimilar drugs
Dr Paul Cornes has received salary from the UK National Health Service and honoraria from several pharmaceutical companies including Roche, Janssen, Sandoz, Lilly, European Generics Association, Teva, and Hospira. The document discusses the increasing cost of cancer drugs and argues that greater use of generics and biosimilars can help contain costs while maintaining treatment effectiveness. It provides examples showing that in the US, increased generic drug use has saved over $1 trillion in healthcare costs in the past decade through lower prices.
Dilip Shanghvi
Dilip Shanghvi founded Sun Pharmaceuticals in 1983 with a loan of Rs. 10,000 from his father. He started the company in Kolkata and later moved headquarters to Mumbai. Sun Pharma has grown to become the fifth largest drug maker in India through strategic acquisitions both in India and abroad. Shanghvi successfully turned around loss-making companies after acquiring them. Sun Pharma focuses on specialty and niche drugs, and over 70% of its sales come from India, though it also has operations in the US.
Biocon H1 q2fy10 11
This partnership between Biocon and Pfizer will enable Biocon's insulin portfolio to have a global presence. Pfizer will have exclusive commercialization rights for Biocon's biosimilar versions of insulin and insulin analogs globally. Biocon will be responsible for clinical development, manufacturing, supply, and regulatory approvals. The agreement is expected to provide upfront and milestone payments totaling $350 million to Biocon. This partnership will help expand access to affordable treatment options for diabetes patients worldwide.
HR PRACTICES AT GSK
GlaxoSmithKline (GSK) is a large British pharmaceutical company formed through a series of mergers over the past 200 years. GSK has a presence in over 170 countries and engages in research and development of pharmaceuticals, vaccines, and consumer healthcare products. The company has a strong focus on ethics and values of patient-focus, integrity, respect for people, and transparency. GSK has a long history in India dating back to 1924 and remains committed to developing and providing affordable medicines to Indian patients.
Sun pharma ranbaxy acquisition
Sun Pharma acquired Ranbaxy in 2014 in a $4 billion deal to become the largest pharmaceutical company in India and fifth largest globally. The acquisition made Sun Pharma the largest Indian pharma company in the US and provided Ranbaxy with API manufacturing capabilities to resume exports to the US. However, Sun Pharma also assumed $800 million of Ranbaxy's debt and regulatory issues remain resolving quality issues at Ranbaxy's plants that were banned by the USFDA. The merger aimed to create synergies but was expected to negatively impact Sun Pharma's financial performance in the near term.
Biosimilars
This document provides an overview of biosimilars. It discusses that biosimilars are similar versions of biologic drugs that are set to lose patent protection. This presents both opportunities to make cheaper biologics to increase access, as well as regulatory challenges to demonstrate similarity. The global biosimilars market is growing, driven by both developed and emerging markets. India is emerging as a key player, with companies developing biosimilars for both domestic and export markets. However, hurdles remain around establishing clear regulatory pathways and demonstrating similarity to reference biologics.
Biosimilars
This document discusses biosimilars and their regulation. It begins with a brief history of biotechnology and biopharmaceuticals. It then defines biosimilars as similar but not generic versions of biologic drugs whose patents have expired. The document outlines key differences between biosimilars and generic drugs, including their larger and more complex molecular structures. It also discusses concerns regarding biosimilar efficacy, safety, interchangeability, and pharmacovigilance. Finally, it provides an overview of regulatory frameworks for biosimilars in various regions like the EU, US, India, and WHO guidelines.
Viewers also liked (18)
6 Hans Wormann - Therapiepotentiale für den Patienten optimal ausschöpfen - g...
6 Hans Wormann - Therapiepotentiale für den Patienten optimal ausschöpfen - g...
Originators and Princeps: How to face Biosimilars and Generics
Originators and Princeps: How to face Biosimilars and Generics
Tefen's Supply Chain Breakfast Meeting - Sun Pharma
Tefen's Supply Chain Breakfast Meeting - Sun Pharma
Analisis trimestral mercado hospitalario IMS Mar 14
Analisis trimestral mercado hospitalario IMS Mar 14
Similar to Sandoz: #SandozHACk #tweetchat
Creating an Integrated International Public Relations Campaign
Here is the presentation from a Public Affairs Council webinar during which I discussed my experience planning and executing a global strategy to align Pfizer with anti-athletic doping efforts.
The Finnish Health Startup Industry Report 2017
Our main goals with this report were to create an overall picture of the health and wellbeing startup industry in Finland, to promote the ecosystem and to strengthen Finland’s position in the sector. This report functions as a tool for development of activities in the ecosystem. We hope that this report gives you a better understanding of the current health startups and the challenges they face.
Don’t kill the analyst just yet – the new world of text analytics
This document is a presentation about using text analytics to accelerate insight generation. It discusses how text analytics can extract usable knowledge from unstructured text data to support decision making. Text analytics allows organizations to explore topics being discussed, sentiment, and provide a single voice of the customer experience. Two case studies are presented, one involving merging feedback from multiple sources for an airline, and another analyzing online discussions about diabetes to understand perceptions of a new drug class. Challenges of text analytics like multiple languages and garbage in/garbage out are also addressed.
Joint Working workshop
The document discusses a quality premium program that rewards clinical commissioning groups for improvements in quality and outcomes. It explains that the premium is based on performance on 4 national measures and 3 local measures selected by each CCG. The national measures relate to reducing mortality, emergency admissions, patient experience, and infections. For a sample CCG, emergency admissions are a major issue, with over 56,000 total admissions last year. Selecting local measures that help achieve the national measures, like reducing emergency admissions, could maximize the CCG's quality premium payment.
Szinapszis credentials 2016
Szinapszis is a European research company based in Hungary that has over 18 years of experience conducting research. It has expertise researching markets in 20 European countries and owns facilities and fieldwork operations in 4 countries. The company offers a variety of integrated research solutions including custom research, a health panel of over 27,000 members, consulting services, data analysis, and publishing research reports. Szinapszis works with pharmaceutical and healthcare clients on projects such as brand tracking, physician surveys, and marketing strategy.
Teaching analysis tools for infodemic managers
Scenario-based group class work for teaching differnet analytical tools for evidence generation in infodemic management. For Master of Public Health course - in class work.
C603 regional health observatory-its role in the generation and dissemination...
The Regional Health Observatory (RHO) of the Pan American health Organization (PAHO) is presented, highlighting its objective, functions and components. Its role as a mean to facilitate access to health data, disseminate health information and evidence to support decision-making in public health is also illustrated. Nowadays, the Health Observatory is an essential and key health information resource for PAHO, Member States, public health professionals and civil society.
Crowdsourcing a strategy for #FutureNHS #AHPsMandate
The document summarizes the process of crowdsourcing input from Allied Health Professionals (AHPs) in the UK to develop a strategy and mandate for change in the NHS. Over 1,900 AHPs from across the UK and other countries provided over 16,000 contributions online over two phases to identify key challenges and priorities. Analysis of the input revealed four ways AHPs can impact the health system and four commitments, as well as four themes and 16 specific enablers to realize their potential. The crowdsourcing approach engaged more people than traditional methods and generated valuable insights to inform the upcoming "#AHPsmandate" strategy to be launched in October 2016.
Kinetic advisory boards
Ashfield Healthcare provides full-service advisory boards to pharmaceutical companies. They apply a consultative "Kinetic" approach to advisory boards that involves challenging objectives, bringing the right advisors, expert facilitation using interactive tools, and producing actionable outputs. Their methodology aims to make advisory boards strategic cornerstones that shape the client's journey. They highlight case studies where their approach led to engaged discussions, consensus on tangible plans, and implementation of agreed actions.
Informing Healthier Choices Case Study
3 year Department of Health public health programme delivered as part of the findings of the Wanless Report in 2004.
How to build a sustainable reputation when your sector faces negative opinions
On 10 October 2019 I presented a case about reputation management at the 4th PR&Communication Summit in Düsseldorf. Nowadays the general public expects transparancy from corporates. People want to know how companies take their social responsibility. In a regulated sector like the pharmaceutical industry you have to deal with rules about what to say and what to say not. That means that you have to be very creative. In this presentation I show how Roche Netherlands is trying to restore trust so we are seen as a healthcare partner in the change for a sustainable healthcare system: personalised health.
Medical presentation 1
Health Research International GmbH is a global health marketing research consultancy founded in 1995. It has grown to have offices in Hamburg, Germany; Barcelona, Spain; and San Diego, USA. The company provides qualitative and quantitative marketing research for over 450 life sciences projects annually, involving interviews and focus groups with over 10,000 healthcare professionals and patients worldwide. Areas of expertise include concept development and testing, branding, messaging, market analysis, and more across therapeutic areas from head to toe. Key clients include brands for conditions like COPD, diabetes, eye diseases, and others.
Presentation of the PICASO Project at WHINN Conference, October 2016
Presentation of PICASO in the session on integrating health and social care by Jesper Thestrup from partners In-JeT ApS
WHINN: Week of Health and INNovation, October 2016
Digital Content for Physicians in Global Markets
Overview of emerging trends in physician digital behavior and engagement opportunities across 22 global markets in Latin America, Asia Pacific, the Middle East, and other emerging markets.
• Partnerships with local publishers to distribute content
• Social networks as a critical physician resource
• Demand for patient-oriented and value-added information and services in the evolving healthcare ecosystem
E-Health Knowledge Management
Lecture on Life Science Forum Basel: eHealth Quo Vadis - How Soon Can Internet Knowledge Replace My Physician
EPIS meeting - Dr Derick Mitchell - October 2017
Derick Mitchell gave a talk on sustaining patient engagement resources through public-private platforms. Some key points:
1. He discussed IPPOSI, a patient-led organization that advocates for patient involvement in health innovation and research.
2. Patient organizations and industry can interact by moving past compliance and instead measuring the value of their interactions through trust and transparency.
3. Generating patient-based evidence through patient registries, mobile apps, and other tools can provide cost-effective, patient-relevant data to inform decision making.
SMRH Working Group
The Reproductive Health Supplies Coalition (RHSC) and its Maternal Health Supplies Caucus work to ensure global access to affordable, high-quality reproductive and maternal health supplies. The RHSC has 328 members from various sectors and its vision is that all people can access contraceptive supplies for better health. The Maternal Health Supplies Caucus was formed in 2012 to address bottlenecks undermining access to essential medicines for maternal health. The Caucus has published briefs on key maternal medicines and business cases to increase investment in their production. Persistent challenges to access include issues with policy harmonization, forecasting, quality assurance, financing, and specific product presentations or storage concerns. Next steps involve market shaping strategies and field testing
Getting Started in the Field of Cross Cultural Learning and Organizational De...
Getting Started in the Field of Cross Cultural Learning and Organizational De...Catherine (Cass) Mercer Bing
Here is advice on how to embark on a career in cross-cultural learning and organizational development from John Bing, founder of ITAP International. The presentation begins with a consideration of one's motives for seeking a career in this field. It suggests where one might look for work. It then discusses John Bing's career path starting with his service in the Peace Corps in Afghanistan. After founding ITAP, John Bing collaborated with Geert Hofstede in the creation of the Culture in the Workplace QuestionnaireTM (CWQ).IHC Case Study Dec 2010
The Informing Healthier Choices Programme was established by the UK Department of Health to improve the availability and use of health information and intelligence across England. It had four aims: 1) improving workforce training, 2) improving local data and tools, 3) strengthening organizations' use of intelligence, and 4) developing web-based support. Major outcomes included enhanced online training, local health profiles and disease models, tools for health impact assessments, and a public health portal. The programme was delivered on time and under budget through collaborative working groups and oversight from a steering committee representing key stakeholders.
Mapping Global Health Leadership in Child Health
This document summarizes findings from interviews and a review on global health leadership in child health. It finds that while child mortality has significantly reduced, challenges remain. Child health needs reframing to emphasize equity and a holistic approach. Leadership has been fragmented and recommendations include designating a lead organization, pursuing champions, and better coordination at both global and country levels. Data and accountability also need strengthening to monitor child health goals.
Similar to Sandoz: #SandozHACk #tweetchat (20)
Creating an Integrated International Public Relations Campaign
Creating an Integrated International Public Relations Campaign
Don’t kill the analyst just yet – the new world of text analytics
Don’t kill the analyst just yet – the new world of text analytics
C603 regional health observatory-its role in the generation and dissemination...
C603 regional health observatory-its role in the generation and dissemination...
Crowdsourcing a strategy for #FutureNHS #AHPsMandate
Crowdsourcing a strategy for #FutureNHS #AHPsMandate
How to build a sustainable reputation when your sector faces negative opinions
How to build a sustainable reputation when your sector faces negative opinions
Presentation of the PICASO Project at WHINN Conference, October 2016
Presentation of the PICASO Project at WHINN Conference, October 2016
Getting Started in the Field of Cross Cultural Learning and Organizational De...
Getting Started in the Field of Cross Cultural Learning and Organizational De...
Recently uploaded
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Histololgy of Female Reproductive System.pptx
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeProf. Marcus Renato de Carvalho
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
The Best Ayurvedic Antacid Tablets in India
Treat the symptoms of indigestion, heartburn and stomach reflux with the 10 Best Ayurvedic Antacid Tablets in India.
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
It includes regulation of combination products and medical devices. FDA and industry liaisons.
The Electrocardiogram - Physiologic Principles
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Efficacy of Avartana Sneha in Ayurveda
Avartana Sneha is a unique method of Preparation of Sneha Kalpana in Ayurveda, mainly it is indicated for the Vataja rogas.
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxMGM SCHOOL/COLLEGE OF NURSING
Identification and nursing management of congenital malformations Top Effective Soaps for Fungal Skin Infections in India
Swisschem Dermacare has mentioned the List of The Best Antifungal Soap In India 2022. All of these soaps are trusted by various Dermatology Experts.
ABDOMINAL TRAUMA in pediatrics part one.
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Adhd Medication Shortage Uk - trinexpharmacy.com
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Recently uploaded (20)
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
Sandoz: #SandozHACk #tweetchat
- 1. Sandoz HACk tweetchat External Communications Holzkirchen November 9, 2016 Global Communications
- 2. Business Unit/Franchise Sandoz HACk tweetchat • The Sandoz HACk tweetchat took place on November 9, 2016 • Its objective was to engage external stakeholders around access to healthcare topics • To stimulate discussion, we used data from the Sandoz Healthcare Issues Perception Survey (SHIPS) – a study of over 7,000 members of the public and 500 health- care experts in 12 countries and other resources • The following slides summarise the key information shared during the tweetchat Business Use Only2
- 3. Business Unit/Franchise Sandoz HACk tweetchat Leveraging learnings from Sandoz Healthcare Issues Perception Study (SHIPS) Business Use Only3
- 4. Business Unit/Franchise Sandoz HACk tweetchat Leveraging learnings from Sandoz Healthcare Issues Perception Study (SHIPS) Business Use Only4
- 5. Business Unit/Franchise Sandoz HACk tweetchat Leveraging learnings from Sandoz Healthcare Issues Perception Study (SHIPS) Business Use Only5
- 6. Business Unit/Franchise Sandoz HACk tweetchat Leveraging learnings from Sandoz Healthcare Issues Perception Study (SHIPS) Business Use Only6
- 7. Business Unit/Franchise Sandoz HACk tweetchat Leveraging learnings from Sandoz Healthcare Issues Perception Study (SHIPS) Business Use Only7
- 8. Business Unit/Franchise Sandoz HACk tweetchat Leveraging learnings from Sandoz Healthcare Issues Perception Study (SHIPS) Business Use Only8 Aging population will strain healthcare systems
- 9. Business Unit/Franchise Sandoz HACk tweetchat Universal access to healthcare: the single largest unmet medical need Business Use Only9
- 10. Business Unit/Franchise Sandoz HACk tweetchat Universal access to healthcare: the single largest unmet medical need Business Use Only10
- 11. Business Unit/Franchise Sandoz HACk tweetchat Universal access to healthcare: the single largest unmet medical need Business Use Only11
- 12. Business Unit/Franchise Sandoz HACk tweetchat Universal access to healthcare: the single largest unmet medical need Business Use Only12
- 13. Business Unit/Franchise Sandoz HACk tweetchat Universal access to healthcare: the single largest unmet medical need Business Use Only13